New Drug Research: Tofacitinib \u0026 ALS

(2:39)

Efficacy and safety of tofacitinib following inadequate response to conventional antirheumatic drugs

(6:2)

Tofacitinib | JAK (Janus Kinase Pathway) Inhibitor Tofacitinib - pharmacology, mechanism of action.

(5:45)

ACR 2020 | Atul Deodhar discusses a phase 3 trial of tofacitinib in ankylosing spondylitis

(5:37)

JAK Inhibitors vs Steroids What's REALLY Better for ARTHRITIS?

(11:2)

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

(4:34)

Tofacitinib as Monotherapy Following MTX Withdrawal in PsA: Dr. Eric Ruderman

(1:31)

5 Questions on Tofacitinib/PsA FDA Hearing - Dr. Jack Cush

(12:22)

Flu and Tofacitinib: Dr. Kathryn Dao

(2:27)

ORAL Surveillance Tofacitinib Safety Panel

(20:25)

JAK inhibitors for IBD

(26:43)

ACR 2020 | Marina Magrey comments on a phase 3 trial of tofacitinib in ankylosing spondylitis

(4:25)

JAK (Janus Kinase Pathway) Inhibitor Tofacitinib - pharmacology, mechanism of action, side effects

(3:7)

CV and Cancer Risk with Tofacitinib in RA | NEJM

(2:12)

When to use a JAK inhibitor in RA: Dr. Janet Pope

(5:7)

Xeljanz(Tofacitinib) 5MG Tablets

(5:18)

5 Questions on Tofacitinib/PsA FDA Hearing - Dr. Allan Gibofsky

(9:37)

5 Questions on Tofacitinib/PsA FDA Hearing - Dr. Philip Mease

(11:5)

Dr. Massimo Gadina discusses the promise of using tofacitinib to treat lupus.

(2:40)

Tofacitinib (Xeljanz): A Practical Review

(4:47)